Outcome of Board Meeting

September 22, 2026 BSE Limited, National Stock Exchange of India Limited, Department of Corporate Services, The Listing Department, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Mumbai-400001 Mumbai-400051 Scrip Code: 544545 Symbol: TRUALT Sub: Intimation under Regulation 30(6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board Meeting held on September 22, 2026 Dear Sir/Madam, Pursuant to the provision of Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of TruAlt Bioenergy Limited (the “Company”) at its meeting held today, i.e. Tuesday, September 22, 2026 has inter-alia approved:  The Appointment of Dr. Sarvamangala R Patil (DIN: 07694181) as an Additional Director in the category of Non-Executive Independent (Woman) Director.  The Additional Investment of Rs. 21,42,00,000 in the Equity Shares of Leafiniti Bioenergy Private Limited, Subsidiary of the Company.  The Additional Investment of Rs. 8,26,82,220/- in the equity shares of TruAlt Sumi Gas Private Limited, Subsidiary of the Company.  The Draft Postal Ballot Notice for seeking the approval of shareholders for appointment of Dr. Sarvamangala R Patil (DIN: 07694181) as an Independent Director of the Company.  The Appointment of Mr. Deepak Sadhu, a Practising Company Secretary (Membership No.: 39541 & CP No.: 14992), as Scrutinizer for conducting the Postal Ballot, through e-voting process (Appointment letter and Consent letter of Scrutinizer is enclosed herewith)  Appointment of NSDL as e-voting Agency for facilitating the e-voting process for the Postal Ballot. In this regard, the information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure I, Annexure II, and Annexure III n c l. : A s a b . N o . 3 8 8 5 o m p a n y S o n u K u m o r T r u A l t o u r s f a i t h h a n k i n g y e r e q u e s . M . h e m e e t i n e b s i t e a t u r t h e r t h e o v e e c r e t a r y B i o e n e f u l l y , o u , t y o u t o g o f t h w w w . t r a f o r e m n d C y L i m i n d l y B o a r l t b i o n t i o n i t e li a n c e O t h e a i r e c t o y . c o m f o r m a f f ic e b o v r s c t i o n l l a i l a Brief Profile of Dr. Sarvamangala R Patil (DIN: 07694181) pursuant to the details as required under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 Annexure-I S.No Particulars Details 1. Reason for change viz. Appointment, appointment, re-appointment, resignation, removal, death or otherwise; 2. Date of appointment/re- September 22, 2026 appointment/cessation (as applicable) & term of Dr. Sarvamangala R Patil, appointed as an appointment/re-appointment; Additional Director in the category of Non- Executive Independent (Woman) Director with immediate effect i.e. September 22, 2026, and subject to the approval of the members by way of a special resolution in terms of Regulation 25(2A) of the Listing Regulations, as an Independent Director for a period of one year from September 22, 2026 up to September 21, 2027 (both days inclusive), not liable to retire by rotation. 3. Brief profile (in case of Dr. Sarvamangala R. Patil possesses over two appointment); decades of experience in the fields of biotechnology, academic leadership, institutional development, government advisory, industrial infrastructure development, women entrepreneurship and public-private initiatives. She has extensive experience in promoting industry-academia collaboration, establishing and strengthening biotechnology and applied science institutions, implementing skill development and industry-oriented programmes, and supporting entrepreneurship and enterprise development, particularly for women. She has also served in various institutional and advisory capacities, including as a Member of the State Expert Appraisal Committee (SEAC), Government of Karnataka, Member of the Karnataka State Lake Conservation & Development Authority and Academic Council Member of Gulbarga University. Her academic and professional expertise in microbiology and biotechnology, together with her experience in government and institutional advisory roles, industrial development, sustainability-oriented initiatives and social and economic development, is expected to provide valuable perspective to the Board in matters relating to technology, sustainability, environmental considerations, industrial development, human capital and strategic growth. 4. Disclosure of relationships Dr. Sarvamangala R. Patil does not have any inter- between directors (in case of se relationship with any of the Directors of the appointment of a director) Company. Details as required under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 Annexure-II 1. Name of the target entity Leafiniti Bioenergy Private Limited 2. Whether the additional Yes, Leafiniti Bioenergy Private Limited investment/subscription/acquisition ("Leafiniti") is a subsidiary of the Company, and the Company currently holds 1,40,96,000 would fall within related party equity shares of Rs. 10/- each in Leafiniti transaction(s) and whether the along with its nominee shareholders, promoter/ promoter group/ group constituting 51% of its paid-up equity share companies have any interest in the capital. The proposed Transaction shall be entity being acquired? If yes, carried out at arm length basis. nature of interest and details thereof and whether the same is done at “arm’s length”; 3. Industry to which the entity Bioenergy and Renewable Energy Industry- being acquired belongs; primarily engaged in the production and selling of compressed biogas and allied products. 4. Objects and impact of additional In order to support the growth and expansion investment/subscription/acquisitio plans of the Subsidiary, to maintain the Company's proportionate shareholding in the n (including but not limited to, Subsidiary and alignment with the Company's disclosure of reasons for such strategic objectives in the bioenergy sector, it additional investment of target is proposed to invest an Additional Rs. entity, if its business is outside the 21,42,00,000/-. This is in line with SSSHA main line of business of the listed dated August 11, 2025. entity); 5. Brief details of any governmental or regulatory NA approvals required for the additional investment/subscription/acquisition 6. Indicative time period for 10.10.2026 completion of the additional investment/subscription/acquisitio; 7. consideration - whether In Cash through Banking Channel cash consideration or share swap or any other form and details of the same; 8. Cost of additional Rs. 21,42,00,000/- i.e 2,14,20,000 Equity investment/subscription/acquisition Shares of Rs. 10 each i.e. at Par and/or the price at which the shares are acquired; 9. Percentage of shareholding / 51% control acquired and / or number of shares acquired; 10. Brief background about the entity Leafiniti Bioenergy Private Limited (“the acquired in terms of products/line Company”) was incorporated as a private of business acquired, date of limited company on February 07, 2020 under incorporation, history of last 3 the provisions of the Companies Act, 2013. years turnover, country in which The Company is into the business of the acquired entity has presence production and selling of compressed biogas and any other significant and allied products i.e. Fermented Organic information (in brief); Manure (FOM), Liquid Fermented Organic Manure (LFOM) from waste or bio-mass sources like sugarcane press mud agricultural residue, cattle dung etc. after purifica [Showing first 8,000 characters — download PDF for full document]